natgillin/translations-raw huggingface dataset:
Serum calcium should be measured and hypocalcaemia must be corrected before initiating zoledronic acid therapy.
Pred začetkom zdravljenja z zdravilom Zoledronska kislina Mylan je treba izmeriti vrednost kalcija v serumu in odpraviti morebitno hipokalciemijo.
Serum calcium should be measured within 1 week after initiation or dose adjustment of cinacalcet.
Kalcij v serumu je treba izmeriti v roku 1 tedna po začetku zdravljenja oz. prilagoditvi odmerka cinakalceta.
Serum calcium should be measured within 1 week after initiation or dose adjustment of Mimpara.
Kalcij v serumu je treba izmeriti v roku 1 tedna po začetku zdravljenja oz. prilagoditvi odmerka zdravila Mimpara.
Serum calcium value or clinical symptoms of hypocalcae mia
Vrednost kalcija v serumu ali klinični simptomi hipokalcie mije
Serum calcium value or clinical symptoms of hypocalcaemia
Vrednost kalcija v serumu ali klinični simptomi hipokalciemije
Serum cholesterol and glucose were minimally to mildly increased in rats but not in mice or dogs.
Serumski holesterol in glukoza sta se pri podganah zvišala minimalno do blago, pri miših in psih pa se nista zvišala.
Serum cholesterol and triglycerides should be tested before and during treatment with Torisel.
Serumski holesterol in trigliceride je treba izmeriti pred zdravljenjem z zdravilom Torisel in med njim.
Serum cholesterol was elevated in rodents but not dogs, while triglycerides were elevated only in mice.
Holesterol v serumu se je zvišal pri glodalcih, ne pa pri psih, medtem ko so se trigliceridi zvišali samo pri miših.
Serum concentration of peginterferon beta-1a was dose-proportional in the range of 63 to 188 micrograms as observed in a single dose and a multiple dose study in healthy subjects.
Koncentracija peginterferona beta-1a v serumu je bila sorazmerna z odmerkom in v razponu od 63 do 188 mikrogramov, kot so opazili pri zdravih osebah v študiji z enim odmerkom in z več odmerki.
Serum concentrations
Koncentracije v serumu
Serum concentrations may be increased due to Breast Cancer Resistance Protein (BCRP) and acute P-gp inhibition by ritonavir.
Serumske koncentracije se lahko povečajo zaradi proteina odpornosti proti raku dojke (BCRP) in akutne inhibicije P-gp z ritonavirjem.
Serum concentrations may be increased due to CYP3A and P-gp inhibition by Kaletra.
Amiodaron, dronedaron: zaradi zavrtja CYP3A z zdravilom Kaletra se koncentracija v serumu lahko zviša.
Serum concentrations may be increased due to CYP3A and P-gp inhibition by Kaletra.
Zaradi zavrtja CYP3A in P-gp z zdravilom Kaletra se koncentracija v serumu lahko zviša.
Serum concentrations may be increased due to CYP3A and P-gp inhibition by Kaletra.
Zaradi zavrtja CYP3A in P-gp z zdravilom Kaletra se lahko koncentracija v plazmi zviša.
Serum concentrations may be increased due to CYP3A and P-gp inhibition by ritonavir.
Serumske koncentracije se lahko povečajo zaradi CYP3A in P-gp inhibicije z ritonavirjem.
Serum concentrations may be increased due to CYP3A inhibition by Kaletra.
koncentracija v serumu lahko
Serum concentrations may be increased due to CYP3A inhibition by Kaletra.
Zaradi zavrtja CYP3A z zdravilom Kaletra se koncentracija v serumu lahko zviša.
Serum concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir.
zaradi zavrtja P-glikoproteina z lopinavirjem/ritonavirjem se lahko koncentracija v plazmi poveča.
Serum concentrations of obinutuzumab in offspring were similar to those in the mothers on day 28 post-partum.
Koncentracija obinutuzumaba v serumu pri potomcih 28. dan po porodu je bila podobna kot pri materah.
Serum concentrations of testosterone and SHBG in patients receiving Intrinsa in clinical safety and efficacy studies
Koncentracije testosterona in SHBG v serumu pri bolnicah, ki so prejemale zdravilo Intrinsa v kliničnih študijah varnosti in učinkovitosti
Serum concentrations of testosterone and SHBG in patients receiving Livensa in clinical safety and efficacy studies
Koncentracije testosterona in SHBG v serumu pri bolnicah, ki so prejemale zdravilo Livensa v kliničnih študijah varnosti in učinkovitosti
Serum creatine phosphokinase (CK) increased
zvišana vrednost kreatin-kinaze
Serum creatinine
kreatinin v serumu
Serum Creatinine (mg/dl)
koncentracija kreatinina v serumu (mg/dl)
serum creatinine (µmol/L)
kreatinin v serumu (µmol/l)
serum creatinine (mol/l)
kreatinin v serumu (mol/l)
Serum creatinine at Day - X
kreatinin v serumu na dan - X
Serum creatinine equal to or greater than 2 × baseline; or
Kreatinin v serumu enak ali večji 2-kratni izhodiščni vrednosti; ali
Serum creatinine increased
zvišana vrednost kreatinina v serumu
Serum creatinine increased
zvišanje ravni kreatinina v serumu
Serum creatinine levels (prior to treatment initiation and at monthly intervals thereafter)
Raven kreatinina v serumu (pred uvedbo zdravljenja in nato v mesečnih presledkih)
Serum creatinine levels should be obtained prior to initiation of treatment and at monthly intervals thereafter until 48 months after the last infusion.
Pred uvedbo zdravljenja in nato v mesečnih presledkih do 48 mesecev po zadnjem infundiranju je treba določati serumske ravni kreatinina.
Serum creatinine, creatinine clearance (estimated with the Cockcroft-Gault or MDRD formula in adults and with the Schwartz formula in children) and/or plasma cystatin C levels should be monitored prior to therapy, weekly in the first month after initiation or modification of therapy with EXJADE, and monthly thereafter.
Koncentracijo kreatinina v serumu, očistek kreatinina (ocenjen po Cockcroft-Gaultovi ali MDRD formuli pri odraslih in po Schwartzovi formuli pri otrocih) in/ali vrednost cistatina C v serumu je treba najprej določiti pred začetkom zdravljenja, v prvem mesecu po uvedbi ali spremembi zdravljenja z zdravilom EXJADE jo je treba spremljati tedensko, kasneje pa enkrat mesečno.
Serum CRP change from baseline to Week 6, median (mcg/mL)
Sprememba serumskega CRP od izhodišča do 6. tedna, mediana vrednost (μg/ml)
Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect.
Kontrolirati je treba koncentracijo digoksina v serumu in izvide uporabiti za titriranje odmerka digoksina, da bi dosegli ţeleni klinični učinek.
Serum ferritin
feritin v serumu
Serum HBV DNA levels remained undetectable and ALT levels normalised in approximately two thirds of patients following treatment with adefovir dipivoxil for up to 240 weeks.
Vrednosti serumske HBV DNA so ostale nezaznavne in vrednosti ALT so se normalizirale pri približno dveh tretjinah bolnikov po zdravljenju z dipivoksiladefoviratom do 240. tedna.
Serum Herpes Simplex Virus Type 2 Infection, N (%)
Serumska okužba z virusom herpes simplex tipa 2, N (%)
Serum insulin levels returned to baseline 15–18 hours after a subcutaneous dose.
Koncentracija insulina v serumu se je vrnila na izhodiščno od 15 do 18 ur po subkutanem odmerku.
Serum LDL was increased in both male and female groups at Day 29.
LDL v serumu je bil zvišan tako pri skupinah moških kot žensk na 29. dan.
Serum levels of 0.5 to 0.9 g/ml are needed to saturate the IL-2 receptor and levels of 5-10 g/ml are needed to inhibit IL-2 mediated biologic activity.
Za zasičenje receptorjev IL-2 so potrebni serumski nivoji od 0,5 do 0,9 g/ml, za zaviranje z IL-2 vodene biološke aktivnosti pa nivoji od 5-10 g/ml.
Serum levels of amprenavir can be reduced by concomitant use of the herbal preparation St John’s wort (Hypericum perforatum).
Serumske koncentracije amprenavirja se lahko ob sočasni uporabi rastlinskih pripravkov iz šentjanževke (Hypericum perforatum) znižajo.
Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after Humira administration.
Po uporabi zdravila Humira se je zmanjšala tudi serumska raven matriksnih metaloproteinaz (MMP-1 in MMP-3), ki povzročajo remodeliranje tkiva, odgovorno za uničenje hrustanca.
Serum levels were below the detection limit 16 and
Serumske koncentracije so bile pod mejo detekcije 16 oz.
Serum liver tests should be monitored before initiation of treatment with pazopanib and at weeks 3, 5, 7 and
Serumske jetrne teste je treba kontrolirati pred uvedbo zdravljenja s pazopanibom ter 3., 5., 7. in
Serum neutrali-sing antibody
Nevtra-lizira-joča proti- telesa v serumu
Serum neutrali-sing antibody
Nevtralizirajoča protitelesa v serumu
Serum neutralising antibody
Nevtra- lizirajoča protitelesa v serumu
Serum neutralising antibody
Nevtralizirajoča protitelesa v serumu
Serum or plasma and/or salivary cortisol and/or urinary free cortisol levels should be monitored, within one week following Ketoconazole HRA initiation as a minimum, and then periodically thereafter.
Največ en teden po uvedbi zdravljenja z zdravilom Ketokonazol HRA je treba preveriti ravni kortizola v serumu ali plazmi in/ali slini in/ali prostega kortizola v urinu, potem pa jih redno spremljati.
Serum potassium and phosphate levels should be monitored regularly during NeoRecormon therapy.
Med zdravljenjem z zdravilom NeoRecormon moramo redno določati serumske koncentracije kalija in fosfata.
Serum potassium decreased
znižana koncentracija kalija v serumu
Serum potassium increased
zvišana koncentracija kalija v serumu
Serum potassium should be monitored during therapy since renal excretion of phenylacetylglutamine may induce a urinary loss of potassium.
Med zdravljenjem je treba spremljati serumski kalij, ker utegne izločanje fenilacetilglutamina skozi ledvici povzročiti izgubo kalija z urinom.
Serum samples from 283 subjects (224 treated with idarucizumab) were tested for antibodies to idarucizumab before and after treatment.
Serumske vzorce 283 preizkušancev (224 zdravljenih z idarucizumabom) so testirali za protitelesa na idarucizumab pred zdravljenjem in po njem.
Serum samples from more than 440 patients across the CLL clinical program were tested for anti-ofatumumab antibodies (either by enzyme-linked immunosorbent assay or electrochemiluminescence) during and after treatment periods ranging from 4 to 45 weeks.
Vzorce seruma več kot 440 bolnikov v celotnem kliničnem programu pri KLL so testirali glede protiteles proti ofatumumabu (z encimsko vezanim imunosorbentnim preizkusom ali z elektrokemoluminiscenco) med zdravljenjem in v obdobju od 4 do 45 tednov po zdravljenju.
Serum sickness
istema
Serum sickness and serum sickness-like reactions, which are delayed allergic type III reactions, have been seen in patients treated with humanised monoclonal antibodies including omalizumab.
Pri bolnikih, zdravljenih s humaniziranimi monoklonskimi protitelesi, med katera sodi tudi omalizumab, so opažali serumsko bolezen in njej podobne reakcije, ki so zapoznele alergijske reakcije tipa III.
Serum sickness,
erumska bolezen,
Serum sickness, anaphylactoid reactions
serumska bolezen, anafilaktoidne reakcije
Serum sickness, anaphylactoid reactions cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
Serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)
Serum sickness, anaphylactoid reactions, cross reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
Serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)
Serum sickness, Anaphylaxis, Polyarteritis nodosa
erumska bolezen, anafilaksija, nodozni poliarteritis
Serum sickness, may include fever and lymphadenopathy
serumska bolezen, lahko vključuje zvišano telesno temperaturo in limfadenopatijo
Serum sickness-like reaction
reakcija, podobna serumski bolezni
serum sodium decrease
znižanje vrednosti natrija v serumu
Serum transaminase increased (in association with hypersensitivity skin reactions)
povečanje serumskih transaminaz (v povezavi s preobčutljivostnimi kožnimi reakcijami)
Serum transaminase levels should be measured prior to starting treatment, every two weeks for the first three months of treatment, and monthly thereafter.
Koncentracije aminotransferaz v serumu je treba najprej izmeriti pred začetkom zdravljenja, nato pa prve tri mesece zdravljenja vsaka dva tedna in kasneje enkrat na mesec.
Serum transaminases should be measured prior to starting treatment, every two weeks for the first three months of treatment and monthly thereafter.
Koncentracije aminotransferaz v serumu je treba izmeriti pred začetkom zdravljenja, v prvih treh mesecih zdravljenja na vsaka dva tedna, nato pa enkrat na mesec.
Serum transaminases, bilirubin, alkaline phosphatase
aminotransferaze v serumu, bilirubin, alkalna fosfataza
Serum urate levels were maintained over time (i.e.
Nivo serumskih uratov se je ohranil skozi celotno obdobje zdravljenja (tj.
Serum uric acid
Sečna kislina v serumu
Servier Danmark A/S Tlf: +45 36 44 22 60
Servier Denmark A/S Tlf: +45 36 44 22 60
Serviço local de Atendimento ao utilizador de EXUBERA
Lokalne telefoniczne centrum informacyjne dla pacjenta
Set and control the rate as explained in section 4.2.
Nastavite in nadzirajte hitrost infuzije, kot je opisano v poglavju 4.2.
SET and RESET evaluated the duration and timing of nighttime sleep and daytime naps via patient-recorded diaries.
V študijah SET in RESET so ocenjevali trajanje in čas spanja ponoči in dremeža podnevi glede na zapise v dnevnikih bolnikov.
Set dose
Nastav ite odmer ek
Set dose
Nastavite odmerek
SET Study
Študija SET
Set the cap aside by placing it with the top down on a flat surface.
Pokrovček odložite z zgornjim delom na ravno površino.
Set the clock/timer for 15 minutes.
Nastavite uro/štoparico na 15 minut.
Set the clock/timer for 30 minutes.
Nastavite u 0 minut.
Set the dose that was prescribed by your doctor (in the example shown in the figure, it is 50 IU).
Nastavite odmerek, ki vam ga je predpisal vaš zdravnik (v prikazanem primeru na sliki je 50 i.e.).
Set the dose to the missing amount you recorded in the treatment diary or the number still displayed in the Dose Feedback Window on your previous pen, and inject.
Nastavite odmerek na manjkajočo količino, ki ste jo zabeležili v dnevnik zdravljenja, ali številko, prikazano v okencu za prikaz odmerka predhodnega napolnjenega injekcijskega peresnika, in injicirajte.
Set the package down with the clear side of the package facing up.
Odložite ovojnino s prozorno stranjo obrnjeno navzgor.
Set the syringe down carefully on the work-surface taking care not to touch the needle.
Brizgo previdno položite na delovno površino in pri tem pazite, da se ne dotaknete igle.
Set the top of the case aside.
Odložite pokrov etuija.
Set up
IME ZDRAVILA
Set up a permanent storage area in a convenient location out of the sight and reach of children so that your Extavia and other supplies are always easy to find.
Izberite trajno, primerno, otrokom skrito in nedostopno mesto, kjer boste imeli zdravilo Extavia in druge pripomočke vedno pri roki.
Set up a permanent storage area in a convenient location out of the sight and reach of children so your Betaferon and other supplies are always easy to find.
Izberite stalno, primerno, otrokom nedosegljivo mesto, kjer boste imeli zdravilo Betaferon in druge pripomočke vedno pri roki.
Set up the following items on a clean surface
Na čisto površino pripravite naslednje:
Set up the following items on a clean surface
Na čisto površino pripravite:
Set up the following items on a clean surface, DO NOT take them out of their individual packaging yet.
Na čisto površino pripravite sledeče enote zdravila in jih NE JEMLJITE iz njihove posamezne ovojnine:
Set up your insulin inhaler
Pripravite insulinski inhalator
setting of the combination
kombiniranem zdravljenju s
Setting the device for the correct concentration of nitric oxide to be administered
Nastavitev naprave za dovajanje pravilne koncentracije dušikovega oksida
Setting the dose prescribed by your doctor
Nastavitev odmerka, ki ga je predpisal vaš zdravnik
Setting the dose to 250”)
Nastavitev odmerka na 250").
Setting the dose to 250”.
Nastavitev odmerka na 250".
Setting the dose – “How to set the dose to 250”
Nastavitev odmerka – "Kako nastaviti odmerek na 250"
Setting the NO, NO2 and O2 monitors for high and low alarm limits
Nastavljanje nadzornih naprav za alarmne signale pri visokih in nizkih koncentracijah NO, NO2 in O2
Setting up
Priprava
Setting up
Priprava na injiciranje
Sevelamer
Sevelamerijev karbonat
Sevelamer carbonate treatment should be re-evaluated in patients who develop severe gastrointestinal symptoms.
Pri bolnikih, ki se jim pojavijo hudi simptomi povezani s prebavili, je treba zdravljenje s sevelamerijevim karbonatom znova oceniti.
Sevelamer carbonate Zentiva 2.4 g powder for oral suspension
Sevelamer carbonate Zentiva 2,4 g prašek za peroralno suspenzijo
Sevelamer carbonate Zentiva 2.4 g powder for oral suspension sevelamer carbonate
Sevelamer carbonate Zentiva 2,4 g prašek za peroralno suspenzijo sevelamerijev karbonat
Sevelamer carbonate Zentiva 800 mg film-coated tablets
Sevelamer carbonate Zentiva 800 mg filmsko obložene tablete
Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate
Sevelamer carbonate Zentiva 800 mg filmsko obložene tablete sevelamerijev karbonat
Sevelamer carbonate Zentiva contains sevelamer carbonate as the active ingredient.
Zdravilo Sevelamer carbonate Zentiva vsebuje sevelamerijev karbonat kot zdravilno učinkovino.
Sevelamer carbonate Zentiva contains sevelamer, a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium.
Zdravilo Sevelamer carbonate Zentiva vsebuje sevelamer, neabsorbtiven premrežen polimer, ki veže fosfate in ne vsebuje kovin ali kalcija.
Sevelamer carbonate Zentiva contains the active substance sevelamer carbonate.
Zdravilo Sevelamer carbonate Zentiva vsebuje zdravilno učinkovino sevelamerijev karbonat.
Sevelamer carbonate Zentiva does not contain any calcium.
Zdravilo Sevelamer carbonate Zentiva ne vsebuje kalcija.
Sevelamer carbonate Zentiva film-coated tablets are white tablets with SC800 imprinted on one side.
Sevelamer carbonate Zentiva filmsko obložene tablete so bele tablete z natisom SC800 vtisnjenim na eni strani.
Sevelamer carbonate Zentiva has been shown to be as effective as another medicine, Renagel (which also contains sevelamer but as the hydrochloride salt) in reducing blood phosphate levels in patients with chronic kidney disease who were on dialysis.
Zdravilo Sevelamer carbonate Zentiva se je pri zniževanju ravni fosfata v krvi pri bolnikih s kronično boleznijo ledvic, ki prejemajo dializo, izkazalo za enako učinkovito kot zdravilo Renagel (ki prav tako vsebuje sevelamer, vendar v obliki hidroklorida).
Sevelamer carbonate Zentiva is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/L.
Zdravilo Sevelamer carbonate Zentiva je indicirano tudi za nadzor hiperfosfatemije pri odraslih bolnikih s kronično boleznijo ledvic, ki niso na dializi, in imajo raven fosforja v serumu ≥ 1,78 mmol/l.
Sevelamer carbonate Zentiva is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease patients not on dialysis with serum phosphorus > 1.78 mmol/L.
Zdravilo Sevelamer carbonate Zentiva je indicirano tudi za nadzor hiperfosfatemije pri bolnikih s kronično boleznijo ledvic, ki niso na dializi, in imajo raven serumskega fosforja ≥ 1,78 mmol/l.
Sevelamer carbonate Zentiva is available as tablets (800 mg) and as a powder (2.4 g) to be made up into a suspension to be taken by mouth.
Zdravilo Sevelamer carbonate Zentiva je na voljo v obliki tablet (800 mg) in praška (2,4 g) za pripravo suspenzije, ki se jemlje peroralno.
Sevelamer carbonate Zentiva is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.
Zdravilo Sevelamer carbonate Zentiva je indicirano za nadzor hiperfosfatemije pri odraslih bolnikih, ki prejemajo hemodializo ali peritonealno dializo.
Sevelamer carbonate Zentiva is not absorbed and may affect the bioavailability of other medicinal products.
Zdravilo Sevelamer carbonate Zentiva se ne absorbira in lahko vpliva na biološko uporabnost drugih zdravil.
Sevelamer carbonate Zentiva is not absorbed compound and may affect the bioavailability of other medicinal products.
Zdravilo Sevelamer carbonate Zentiva se ne absorbira in lahko vpliva na biološko uporabnost drugih zdravil.
Sevelamer carbonate Zentiva is not indicated for the control of hyperparathyroidism.
Zdravilo Sevelamer carbonate Zentiva ni indicirano za nadzorovanje hiperparatiroidizma.
Sevelamer carbonate Zentiva is unlikely to affect your ability to drive or to use machines.
Ni verjetno, da bi zdravilo Sevelamer carbonate Zentiva vplivalo na vašo sposobnost vožnje in upravljanja s stroji.
Sevelamer carbonate Zentiva is used to control hyperphosphataemia (high blood phosphate levels) in: adult patients on dialysis (a blood clearance technique).
Zdravilo Sevelamer carbonate Zentiva se uporablja za nadzor hiperfosfatemije (visoke ravni fosfata v krvi) pri: odraslih bolnikih na dializi (tehnika čiščenja krvi).
Sevelamer carbonate Zentiva must be taken three times a day with meals and patients should keep to their prescribed diets.
Zdravilo Sevelamer carbonate Zentiva je treba jemati trikrat dnevno z obroki, bolniki pa morajo uživati predpisano dieto.
Sevelamer carbonate Zentiva must be taken three times per day with meals.
Zdravilo Sevelamer carbonate Zentiva je treba jemati trikrat dnevno z obroki.
Sevelamer carbonate Zentiva must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut).
Zdravilo Sevelamer carbonate Zentiva se ne sme uporabljati pri osebah s hipofosfatemijo (nizko ravnjo fosfata v krvi) ali obstrukcijo (zaporo) črevesa.
Sevelamer carbonate Zentiva powder for oral suspension is a pale yellow powder supplied in a foil sachet with a heat seal.
Sevelamer carbonate Zentiva prašek za peroralno suspenzijo je svetlorumeni prašek, na voljo v termično zvarjeni vrečici iz folije.
Sevelamer carbonate Zentiva powder for oral suspension must be taken three times per day with meals.
Zdravilo Sevelamer carbonate Zentiva prašek za peoralno suspenzijo je treba jemati trikrat na dan z obroki.
Sevelamer carbonate Zentiva sevelamer carbonate
Sevelamer carbonate Zentiva sevelamerijev karbonat
Sevelamer carbonate Zentiva should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Zdravilo Sevelamer carbonate Zentiva je treba uporabljati z drugimi zdravili, na primer z dodatki kalcija in vitamina D, za preprečevanje razvoja bolezni kosti.
Sevelamer carbonate Zentiva should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Zdravilo Sevelamer carbonate Zentiva se sme uporabljati sočasno s terapijo preprečevanja razvoja bolezni kosti, v sklopu katere se dodaja kalcij in vitamin D.
Sevelamer carbonate Zentiva should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Zdravilo Sevelamer carbonate Zentiva se sme uporabljati sočasno s terapijo preventive razvoja bolezni kosti pri kateri se dodaja kalcij in vitamin D.
Sevelamer carbonate Zentiva should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Zdravilo Sevelamer carbonate Zentiva je treba uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijev dodatek, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog, za nadziranje razvoja renalne osteodistrofije.
Sevelamer carbonate Zentiva should not be taken at the same time as ciprofloxacin (an antibiotic).
Zdravila Sevelamer carbonate Zentiva ne smete jemati sočasno s ciprofloksacinom (antibiotik).